Study S000530

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01664247
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 346
Start: 2012-10-01
Primary completion: 2013-12-31
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:insulin degludec; DRUG:placebo; DRUG:liraglutide
Results posted: TRUE
Secondary identifiers: EUDRACT_NUMBER:2011-004665-32; OTHER:U1111-1124-6612

Registered primary outcomes

Change From Baseline in Glycosylated Haemoglobin (HbA1c) (%) [Week 0, week 26]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0025746	Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study). Aroda VR, Diabetes, obesity & metabolism	2016	Randomized trial	PMID 26990378 DOI	cites ClinicalTrials.gov:NCT01664247; registry reference RESULT:26990378